0000000000033925

AUTHOR

G. Raneli

showing 12 related works from this author

Haemorheological components in the pre-geriatric and geriatric age range in a randomly selected Western Sicily population sample (Casteldaccia study)

1993

{Received 24.8.1992; accepted 7.12.1992} On a randomly selected western Sicily population sample (Casteldac­ cia Study: 600 subjects; 300 males and 300 females) of an age range from 40 to 79 years, were determined: Haematocrit (Htc) , blood vi­ scosity, plasma viscosity, filterability of whole blood and fibrinogen. Par­ ticipation was 97%, being 582 subjects (M = 287, F = 295). All the parameters measured showed a progressive increase with age and si­ gnificant differences were found between male and female subjects: Htc and blood viscosity were higher in male subjects (p < 0.01), while plasma viscosity, whole blood filterability and fibrinogen were higher in female subjects (p < 0.05). In …

medicine.medical_specialtyPopulation samplePhysiologybusiness.industryBlood viscosityHematologyFibrinogenGastroenterologyCoronary heart diseaseSurgeryPhysiology (medical)Internal medicinemedicineRisk factorCardiology and Cardiovascular MedicinebusinessPlasma viscosityWhole bloodmedicine.drugClinical Hemorheology and Microcirculation
researchProduct

Non lipid, dose-dependent effects of pravastatin treatment on hemostatic system and inflammatory response

2000

Objectives: The aim of the present study was to evaluate the effects of pravastatin treatment on lipid, inflammation, and coagulation parameters in patients suffering from myocardial infarction with or without carotid atherosclerotic lesions (groups 1 and 2, respectively). Methods: In the first phase of the study, a cross-sectional comparison of lipid, inflammation, and coagulation parameters was performed between the patients and the control group (group 3). Highly significant differences in these parameters were observed, especially in group 1. In the second phase of the study, we assessed the effects of a persistent reduction in cholesterol synthesis induced by increasing doses of pravas…

Blood GlucoseMalemedicine.medical_specialtyMyocardial InfarctionInflammationCoronary Artery DiseaseFibrinogenchemistry.chemical_compoundRisk FactorsInternal medicinemedicineHumansPharmacology (medical)PravastatinInflammationPharmacologyDose-Response Relationship DrugFactor VIIbusiness.industryCholesterolpravastatin inflammatory responseGeneral MedicineMiddle AgedBlood Coagulation FactorsCholesterolCross-Sectional StudiesEndocrinologyCoagulationchemistryCase-Control StudiesHemostasisFemalelipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorsmedicine.symptombusinessPravastatinmedicine.drugLipoproteinEuropean Journal of Clinical Pharmacology
researchProduct

Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia.

1995

A randomized double-blind study was carried out with gemfibrozil (600 mg b.i.d.) vs placebo in 20 patients (twelve males and eight females, age 52 +/- 3 years, BMI 24.2 +/- 0.4) suffering from primary hypertriglyceridemia (Fredrickson's type IV). Each group was treated for a 12 week period with gemfibrozil (n = 10) or placebo (n = 10) patients) in a double-blind fashion. Total cholesterol, HDL-cholesterol (HDL-C) and its subfractions (HDL2-C and HDL3-C), blood glucose, Apolipoproteins A1 and B, fibrinogen, plasminogen, factor VII, t-PA:Ag and PAI activity pre- and post-venous occlusion (VO) were determined. In the gemfibrozil-treated group a significant decrease of total cholesterol and tri…

Malemedicine.medical_specialtymedicine.medical_treatmentLipoproteinsFibrinogenchemistry.chemical_compoundDouble-Blind MethodInternal medicineFibrinolysismedicineGemfibrozilHumansTriglyceridesApolipoproteins BHypertriglyceridemiaTriglycerideApolipoprotein A-Ibusiness.industryCholesterolFibrinolysisHypertriglyceridemiaReverse cholesterol transportCholesterol HDLFibrinogenPlasminogenHematologyGeneral MedicineFactor VIIMiddle Agedmedicine.diseaseEndocrinologyCholesterolchemistryTissue Plasminogen Activatorlipids (amino acids peptides and proteins)FemaleGemfibrozilbusinessLipoproteinmedicine.drugBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

We-P13:336 Haemostatic and fibrinolytic abnormalities in obese patients and in patients with type 2 diabetes with metabolic syndrome

2006

medicine.medical_specialtybusiness.industryInternal medicineInternal MedicineMedicineIn patientGeneral MedicineType 2 diabetesMetabolic syndromeCardiology and Cardiovascular Medicinebusinessmedicine.diseaseGastroenterologyAtherosclerosis Supplements
researchProduct

Cross-over study on effects of Mediterranean diet in two randomly selected population samples

2003

Abstract Two randomly selected population samples in Western Sicily, one rural (n = 40) and one urban (n = 40), were studied to evaluate the impact of dietary intervention on lipid, coagulative and fibrinolytic parameters. The two groups received the diets in a cross-over design with the following sequences: (a) baseline period; (b) 8-week dietary intervention period; (c) 8-week return to the original diet. During (a) and (c) all subjects consumed their usual diet. During the dietary intervention period (b), the rural sample consumed the urban sample's diet, while the urban sample consumed the rural sample's diet (the so-called “Mediterranean diet”). At baseline, after 8 weeks' dietary inte…

chemistry.chemical_classificationeducation.field_of_studymedicine.medical_specialtyNutrition and DieteticsMediterranean dietbusiness.industryEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPopulationCrossover studyEndocrinologyAnimal scienceEndocrinologychemistryInternal medicineFibrinolysisSaturated fatty acidmedicineeducationbusinessPlasminogen activatorCompletely randomized designPolyunsaturated fatty acidNutrition Research
researchProduct

Effects of heparin treatment on hemostatic abnormalities in obese non-insulin-dependent diabetic patients.

1997

This study was conducted to identify the mechanisms responsible for coagulative and fibrinolytic alterations and to study the effects of a short-term treatment with low-dose heparin on hemostatic abnormalities in obese non-insulin-dependent diabetes mellitus (NIDDM) patients. Four groups of age- and sex-matched patients were studied: (1) lean nondiabetic subjects (n = 30) with a body mass index (BMI) less than 25 kg/m2 (lean control subjects), (2) obese nondiabetic subjects (n = 30) with a BMI greater than 30 kg/m2 (obese control subjects), (3) lean NIDDM patients (n = 30), and (4) obese NIDDM patients (n = 30). All subjects were tested on the following parameters: fibrinogen, factor VII, p…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentFibrinogenTissue plasminogen activatorBody Mass Indexchemistry.chemical_compoundEndocrinologyInternal medicineFibrinolysismedicineHumansInsulinObesityBlood CoagulationHemostasisFactor VIIbusiness.industryHeparinFibrinolysisnutritional and metabolic diseasesAnticoagulantsHeparinMiddle AgedLipidsBlood Coagulation FactorsEndocrinologychemistryDiabetes Mellitus Type 2HemostasisCase-Control StudiesFemalebusinessPlasminogen activatorBody mass indexmedicine.drugMetabolism: clinical and experimental
researchProduct

Effects of moderate Sicilian red wine consumption on inflammatory biomarkers of atherosclerosis.

2006

Objective: The aim of the study is to evaluate the effect of moderate Sicilian red wine consumption on cardiovascular risk factors and, in particular, on some inflammatory biomarkers. Methods: A total of 48 subjects of both sexes who were nondrinkers or rare drinkers of moderate red wine were selected and randomly subdivided into two groups assigned to receive with a crossover design a Sicilian red wine (Nero d’Avola or Etna Torrepalino) during meals: Group A (n ¼ 24), in whom the diet was supplemented for 4 weeks with 250 ml/day of red wine, followed by 4 weeks when they returned to their usual wine intake; and Group B (n ¼ 24), in whom the usual wine intake was maintained for 4 weeks, fol…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaMediterranean dietMedicine (miscellaneous)WineClinical nutritionFibrinogenDiet Mediterraneanchemistry.chemical_compoundRisk FactorsMediterranean dietInternal medicinemedicineHumansRisk factorAgedWineNutrition and DieteticsCross-Over StudiesFactor VIIbusiness.industryVascular diseasefood and beveragesred wineMiddle Agedmedicine.diseaseAtherosclerosisLipid MetabolismSettore MED/11 - Malattie Dell'Apparato CardiovascolareCrossover studySurgeryhs-CRPEndocrinologyC-Reactive ProteinCholesterolrisk factorchemistryItalyTGFb1red wine; risk factors; TGFb1; hs-CRP; Mediterranean dietFemaleInflammation MediatorsbusinessOxidation-ReductionBiomarkersmedicine.drugEuropean journal of clinical nutrition
researchProduct

Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIb hyperlipoproteinemia

1994

Abstract A randomized, double-blind, parallel-group study of pravastatin versus placebo was carried out for 24 weeks in 20 patients with type IIb primary hyperlipoproteinemia. Total cholesterol, triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, blood glucose, apolipoproteins (apo) A1 and B, and lipoprotein (a) (Lp[a]) levels were determined. A venous occlusion test was also performed in all patients. Pre- and postvenous occlusion tests were determined: tissue plasminogen activator antigen (t-PA[Ag]), plasminogen activator inhibitor (PAI) activity, factor VII, fibrinogen, plasminogen, and hematocrit. Compared with placebo, pravastatin signi…

Pharmacologymedicine.medical_specialtyApolipoprotein BbiologyTriglyceridebusiness.industryCholesterolmedicine.medical_treatmentnutritional and metabolic diseasesFibrinogenchemistry.chemical_compoundEndocrinologychemistryInternal medicineFibrinolysismedicinebiology.proteinlipids (amino acids peptides and proteins)Pharmacology (medical)businessPlasminogen activatorPravastatinmedicine.drugLipoproteinCurrent Therapeutic Research
researchProduct

Coagulation, fibrinolysis and haemorheology in premenopausal obese women with different body fat distribution

1994

Recently waist/hip ratio (WHR), a marker of body fat distribution, has been described as a risk factor for cardiovascular disease (CVD). The aim of the present study was to evaluate the influence of body fat distribution on metabolic, haemostatic and haemorheological pattern in premenopausal obese women with different WHR. Fourty premenopausal obese women were subdivided into two groups, matched for age and body mass index (BMI): 20 women with abdominal obesity (WHR = 0.94 +/- 0.02) and 20 women with peripheral obesity (WHR = 0.77 +/- 0.03). Twenty nonobese women were recruited as control group. The abdominal obesity group had significantly higher blood glucose, triglycerides, total cholest…

Adultmedicine.medical_specialtymedicine.medical_treatmentFibrinogenchemistry.chemical_compoundHigh-density lipoproteinRisk FactorsInternal medicineFibrinolysismedicineHumansObesityBlood CoagulationAbdominal obesitybiologybusiness.industryCholesterolFibrinolysisFibrinogenBlood ProteinsHematologyFactor VIIBlood Viscositymedicine.diseaseLipidsObesityEndocrinologyHematocritPremenopausechemistryCardiovascular DiseasesHemorheologybiology.proteinBody ConstitutionFemaleApolipoprotein A1medicine.symptombusinessBody mass indexmedicine.drugThrombosis Research
researchProduct

Elevated levels of lipoprotein (a) in patients suffering from myocardial infarction with carotid atherosclerotic lesions.

1999

The aim of the present study was to evaluate metabolic, coagulation and fibrinolytic parameters in 45 patients [31 men, 14 women, aged 56.5 +/- 3.5 years (mean +/- SD)] who had suffered myocardial infarction more than 6 months earlier, with or without carotid atherosclerotic lesions. After the extracranial carotid arteries had been evaluated using a B-mode Duplex scanning system, patients were subdivided into two groups: group 1 (n = 20) with carotid plaques or measurable intima-media thickness; and group 2 (n = 25) without carotid plaques or measurable intima-media thickness. Twenty-two age- and sex-matched subjects were recruited as controls (group 3). Groups 1 and 2 displayed significant…

Carotid Artery DiseasesMalemedicine.medical_specialtyArteriosclerosismedicine.medical_treatmentLipoproteinsMyocardial InfarctionFibrinogenBody Mass IndexRisk FactorsInternal medicineFibrinolysismedicineHumansMyocardial infarctionBlood CoagulationTriglyceridesbiologybusiness.industryFibrinolysisHematologyGeneral MedicineLipoprotein(a)Middle Agedmedicine.diseaseEndocrinologyApolipoproteinsCholesterolbiology.proteinCardiologyApolipoprotein A1FemalebusinessPlasminogen activatorProtein CBiomarkersLipoproteinmedicine.drugLipoprotein(a)Blood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

Fibrinolysis in hypertriglyceridaemic subjects in response to venous occlusion.

1993

We have measured various fibrinolytic and coagulation parameters (t-PA antigen, PAI, fibrinogen, plasminogen and factor VII) before and after 10 min of venous occlusion in 20 hypertryglyceridaemic subjects (twelve males and eight females, age 38 +/- 4 years, body mass index 23 +/- 1.5) and 20 healthy normal subjects, matched for sex (twelve males and eight females), age (37 +/- 3.5 years) and body mass index (22.8 +/- 1.4). At rest, t-PA:Ag, PAI, fibrinogen, plasminogen and factor VII were significantly (P < 0.005) higher in hypertriglyceridaemic subjects than in normal controls. After venous occlusion, the increase in all parameters except t-PA:Ag was more marked in the patient group than …

AdultMalemedicine.medical_specialtyPathologymedicine.medical_treatmentFibrinogenHyperlipoproteinemia Type IVVeinschemistry.chemical_compoundAntigenInternal medicineOcclusionFibrinolysisPlasminogen Activator Inhibitor 1medicineHumansFactor VIIbusiness.industryFibrinolysisHypertriglyceridemiaFibrinogenPlasminogenHematologyGeneral MedicineFactor VIIMiddle Agedmedicine.diseaseConstrictionLipidsEndocrinologyApolipoproteinsCoagulationchemistryTissue Plasminogen ActivatorFemalebusinessBody mass indexmedicine.drugBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

Factor VIII and Antithrombin III in Atherosclerosis Obliterans of the Lower Limbs

1984

In the multifactorial pathogenesis of atherosclerosis (the W.H.O. gives a list of about forty risk factors) recent acquisitions have allowed to determine in part the role carried out by the term “haemocoagulative disorders” (90) showing the possible connections between haematic components of haemocoagulation and vascular wall that up to now have been only hypothesised.

Vascular wallPathogenesismedicine.medical_specialtybusiness.industryInternal medicineAntithrombinmedicineCardiologybusinessATHEROSCLEROTIC VASCULAR DISEASEmedicine.drug
researchProduct